Search

Displaying results 7511 - 7520 of 10000 in total
  1. Drug

    Vixotrigine

    go.drugbank.com/drugs/DB11706
    Investigational

    Vixotrigine has been investigated for the treatment of Bipolar Disorder and Bipolar Depression.

  2. Drug

    Pancreatic Polypeptide

    go.drugbank.com/drugs/DB12822
    Investigational

    Pancreatic Polypeptide has been investigated for the treatment of Diabetes Mellitus, Type 1.

  3. Drug

    IOWH-032

    go.drugbank.com/drugs/DB12959
    Investigational

    Iowh032 has been investigated for the treatment of Cholera, Diarrhea, and Secretory Diarrhea.

  4. Drug

    Avagacestat

    go.drugbank.com/drugs/DB11893
    Investigational

    Avagacestat has been investigated for the basic science and treatment of Alzheimer Disease.

  5. Drug

    Tanezumab

    go.drugbank.com/drugs/DB12335
    Investigational

    Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.

  6. Drug

    E-7820

    go.drugbank.com/drugs/DB12505
    Investigational

    E7820 has been investigated for the treatment of Colon Cancer and Rectal Cancer.

  7. Drug

    Apaziquone

    go.drugbank.com/drugs/DB12593
    Investigational

    Apaziquone has been investigated for the treatment of Bladder Cancer and Bladder Neoplasms.

  8. Drug

    Tirilazad

    go.drugbank.com/drugs/DB13050
    Investigational

    Tirilazad has been used in trials studying the treatment of Spinal Cord Injury.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. … It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.

  10. Drug

    EU204

    go.drugbank.com/drugs/DB17438
    Investigational

    EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.